Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?
11:18am, Friday, 19'th Aug 2022
Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.
4 Stocks to Watch Amid Recovering Medical Products Industry
12:32pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised
4 Stocks to Watch Amid Recovering Medical Products Industry
09:47am, Thursday, 18'th Aug 2022
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised
3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock
04:45pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.
3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock
02:18pm, Tuesday, 16'th Aug 2022
Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy
04:00pm, Friday, 12'th Aug 2022 Zacks Investment Research
Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy
01:33pm, Friday, 12'th Aug 2022
Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
06:10pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
03:48pm, Thursday, 11'th Aug 2022
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Where Haemonetics Stands With Analysts
03:04pm, Thursday, 11'th Aug 2022 Benzinga
Within the last quarter, Haemonetics (NYSE:HAE) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
2
0
0
Last 30D
0
Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2023 Results - Earnings Call Transcript
01:42pm, Wednesday, 10'th Aug 2022
Haemonetics Corporation (NYSE:HAE ) Q1 2023 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D'Arecca - CFO Con
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
11:25am, Wednesday, 10'th Aug 2022 Zacks Investment Research
Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
09:02am, Wednesday, 10'th Aug 2022
Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics Surges Closer To A Breakout After Squashing Quarterly Estimates, Raising Guidance
08:55am, Wednesday, 10'th Aug 2022
Haemonetics easily beat fiscal first-quarter estimates on Wednesday and raised its outlook for the year. HAE stock popped.
Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
09:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
